Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Results of an open label feasibility study of sodium valproate in people with McArdle disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Contractile properties are impaired in congenital myopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantitative Muscle MRI and Clinical Findings in Women With Pathogenic Dystrophin Gene Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Myopathy can be a key phenotype of membrin (GOSR2) deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

McArdle disease results from a lack of muscle glycogen phosphorylase in skeletal muscle tissue. Regenerating skeletal muscle fibres can express the brain glycogen phosphorylase isoenzyme. Stimulating expression of this enzyme could be a therapeutic strategy. Animal model studies indicate that sodium valproate (VPA) can increase expression of phosphorylase in skeletal muscle affected with McArdle disease. This study was designed to assess whether VPA can modify expression of brain phosphorylase isoenzyme in people with McArdle disease. This phase II, open label, feasibility pilot study to assess efficacy of six months treatment with VPA (20 mg/kg/day) included 16 people with McArdle disease. Primary outcome assessed changes in VO2peak during an incremental cycle test. Secondary outcomes included: phosphorylase enzyme expression in post-treatment muscle biopsy, total distance walked in 12 min, plasma lactate change (forearm exercise test) and quality of life (SF36). Safety parameters. 14 participants completed the trial, VPA treatment was well tolerated; weight gain was the most frequently reported drug-related adverse event. There was no clinically meaningful change in any of the primary or secondary outcome measures including: VO2peak, 12 min walk test and muscle biopsy to look for a change in the number of phosphorylase positive fibres between baseline and 6 months of treatment. Although this was a small open label feasibility study, it suggests that a larger randomised controlled study of VPA, may not be worthwhile.

Original languageEnglish
JournalNeuromuscular disorders : NMD
Volume30
Issue number9
Pages (from-to)734-741
Number of pages8
ISSN0960-8966
DOIs
Publication statusPublished - Sep 2020

    Research areas

  • 12 min walking test, Glycogen storage disease type V, Outcome measures, Sodium valproate (VPA), VO2peak

ID: 61071630